Vanda Pharmaceuticals Achieves Major Milestone in Motion Sickness Treatment
Vanda Pharmaceuticals Inc. stock is witnessing a remarkable rise in premarket trading, soaring 18.63% to $8.34. This surge follows the announcement that the U.S. Food and Drug Administration has greenlit NEREUS™ (tradipitant). This achievement marks the introduction of the first pharmacologic treatment for motion sickness in over four decades, indicating a significant advancement in medical therapies.
This landmark approval signifies a great stride for the biopharmaceutical company, addressing a condition that impacts millions of individuals across the U.S. each year.
Groundbreaking FDA Approval for NEREUS™
The FDA’s decision to approve NEREUS™ represents a critical turning point in the management of motion sickness, being the first new drug of its kind sanctioned since the early 1980s. NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist, functions by inhibiting a specific brain receptor responsible for nausea and vomiting. This modern approach to treatment offers hope to many who suffer from motion-related ailments.
Vanda anticipates launching NEREUS™ in the upcoming months. Analyst Raghuram Selvaraju from H.C. Wainwright estimates that sales could reach over $100 million annually at peak within the U.S. market alone.
The approval was supported by extensive clinical data derived from three pivotal trials that included a total of 681 patients. Among these, two Phase 3 real-world studies were conducted on boats. The Motion Syros study encompassed 365 participants and demonstrated a reduction in vomiting incidence to 18.3-19.5% with NEREUS™, compared to 44.3% for the placebo group. Meanwhile, the Motion Serifos study exhibited even more favorable results, with vomiting rates between 10.4-18.3% versus 37.7% for placebo.
These studies indicated that NEREUS™ effectively reduces risk by over 50-70%, confirming its efficacy in preventing motion-induced vomiting.
Market Impact and Growth Prospects
Before the announcement of the FDA approval, VNDA closed at $7.03, reflecting a dip of 2.36%. The premarket increase has propelled the stock price to $8.34, representing a gain of $1.31 per share. Vanda has demonstrated a strong year-to-date performance, boasting a 46.76% return, significantly surpassing the S&P 500's 17.25% gain.
With a market capitalization of $415.45 million and a dedicated workforce of 368 employees, Vanda is strategically positioning itself to capture a significant share of the motion sickness treatment market, affecting approximately 25-30% of adults—or around 65-78 million people in the U.S.
Moreover, the company is progressing with tradipitant in clinical trials for various additional indications, including gastroparesis and the management of nausea and vomiting associated with GLP-1 receptor agonists. These side effects are becoming increasingly relevant within the fast-evolving obesity and diabetes treatment sectors. Vanda secured the rights to tradipitant from Eli Lilly in 2012 and has been exploring multiple applications for this innovative compound.
Initially, the FDA had placed a partial clinical hold on tradipitant back in December 2018. However, this hold was lifted on December 4, following the determination that motion sickness is an acute rather than chronic condition. This classification helped pave the way for the recent approval.
Frequently Asked Questions
What is NEREUS™ and what does it treat?
NEREUS™ is an FDA-approved drug from Vanda Pharmaceuticals designed to prevent vomiting caused by motion sickness.
What is the significance of the FDA's approval of NEREUS™?
This approval marks the first new treatment for motion sickness in over 40 years, showcasing advancements in pharmacologic therapies.
How did the stock of Vanda Pharmaceuticals react to the news?
Vanda's stock surged 18.63% to $8.34 in premarket trading following the FDA's approval announcement.
What are the market expectations for NEREUS™?
Analysts predict that NEREUS™ could generate over $100 million in annual sales at peak in the U.S. market.
What other conditions is Vanda exploring with tradipitant?
In addition to motion sickness, Vanda is researching the use of tradipitant for gastroparesis and nausea from GLP-1 receptor agonists.
